KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy Meeting Abstract
| Authors: | Bajorin, D. F.; Plimack, E. R.; Siefker-Radtke, A. O.; Choueiri, T. K.; De Wit, R.; Sonpavde, G.; Gipson, A.; Brown, H.; Mai, Y. B.; Pang, L.; Perini, R. F.; Bellmunt, J. |
| Abstract Title: | KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036904764 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2015.33.15_suppl.tps4572 |
| Notes: | Meeting Abstract: TPS4572 -- Source: Wos |
